8E8.F ELICERA THERAPEUTICS AB

Healthcare Biotechnology Frankfurt Exchange
0.2045 EUR
Close of Nov 11, 2026
0.1786 0.6050
Market cap
EUR 13.6M
P/E
-
P/B
2.68x
ROE
-40.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 8E8.F undervalued?

Graham number

The Graham number of ELICERA THERAPEUTICS AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ELICERA THERAPEUTICS AB fundamental analysis

No fundamental analysis for ELICERA THERAPEUTICS AB yet.

ELICERA THERAPEUTICS AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ELICERA THERAPEUTICS AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatm…

Full company profile